RecruitingNCT06670495

HPV Genotype Attribution and Disease Burden of Anal Cancer in China

Understanding the Human Papillomavirus Genotype Attribution and Disease Burden of Anal Cancer in China: A Multicenter Hospital-based Study


Sponsor

Fudan University

Enrollment

300 participants

Start Date

Jun 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

To demonstrate HPV prevalence and its genotype distributions in anal cancer in China and to describe demographic and clinical features of HPV-related anal cancer in China; To describe the epidemiological characteristics ,trends and of disease burden of anal cancer in China


Eligibility

Plain Language Summary

Simplified for easier understanding

This study in China examines which types (genotypes) of the human papillomavirus (HPV) are most commonly linked to anal cancer. It involves collecting and testing tumor specimens from anal cancer patients to understand the disease burden and which HPV strains are responsible. No treatment is given — this is a surveillance and research study. **You may be eligible if...** - You have been diagnosed with anal cancer - You have not yet received radiation or chemotherapy (so the specimen is unaffected by treatment) **You may NOT be eligible if...** - You have HIV infection - You are on immune-suppressing drugs after an organ transplant - You decline to have your specimen collected and tested - Your specimen is not available (for retrospective cases) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Fudan University Shanghai Cancer Center

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06670495


Related Trials